EP 120: Exploring the frontiers of gene therapy and AAVs with Dr. Nicole Paulk, CEO and Founder of Siren Biotechnology
February 1, 2024
In this episode, we welcome Dr. Nicole Paulk, CEO and Founder of Siren Biotechnology and former professor at University of California at San Francisco (UCSF). Dr. Paulk's journey from academia to the forefront of industry innovation offers a unique perspective into gene therapy and adeno-associated viruses (AAVs). Join us as we explore the futuristic applications of gene editing!
0:00 Introduction to Dr. Nicole Paulk, a pioneer in AAV research and the founder of Siren Biotechnology
0:50 The moments that shaped Nicole’s career path and her passion for gene therapy and AAV research
9:20 Nicole’s academic research career and her transition from academia to the biotech industry
23:00 The story behind the founding of Siren Biotechnology
30:11 Major challenges and breakthroughs in developing Universal AAV Immuno-Gene Therapy and vectorising cytokines.
36:00 Long-term impacts of using gene editing to target oncogenes
37:30 Challenges of 2023 in the startup field and Nicole’s expectations for 2024
42:00 Academia vs. Industry: Research processes and the pace of grant writing and innovation
46:40 Closing remarks